Bright Minds Biosciences Inc.
NASDAQ:DRUGBiotechnology
+$0.62 today
- Market cap
- $204.78M
- Beta
- -0.11
- P/E (TTM)
- -29.8
- EPS (TTM)
- -$2.87
Volume 0.14M
Average 0.27M
DRUG Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Bright Minds Biosciences Inc.NASDAQ: DRUG
Net Change in Cash · Q2 FY2026 · quarter ended Mar 2026
Net change in cash turns positive
Q2 FY2026 net change in cash was CA$218.88M, compared with -CA$2.22M a year earlier. Trailing-twelve-month net change in cash was CA$252.25M.
Context
- Net change in cash increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near CA$218.88M or moves back toward the trailing-twelve-month quarterly average of CA$63.06M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
CAD · from the cash flow
- Latest · FY2025
- 77.19M CAD
- Year-over-year change
- +7609.4%
- 4-year CAGR
- +42.0%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 77.19M | +7609.4% |
| FY2024 | 2024-09-30 | (1.03M) | +78.9% |
| FY2023 | 2023-09-30 | (4.88M) | +40.0% |
| FY2022 | 2022-09-30 | (8.13M) | -142.9% |
| FY2021 | 2021-09-30 | 18.96M | — |
Net Change in Cash vs competitors
How DRUG compares with its peers on the latest reported figures
No competitor Net Change in Cash figures are available to compare.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (8.65M) | (14.96M) | (7.37M) | (2.8M) | (12.23M) |
| Depreciation & Amortization | 0 | 6.04K | 72.45K | 73.36K | 76.87K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 880.62K | 875.06K | 1.15M | 839.77K | 3.18M |
| Change in Working Capital | 306.08K | 724.13K | (941.72K) | 39.81K | 554.99K |
| Accounts Receivables | (110.15K) | (45.63K) | 118.8K | (13.24K) | (362.85K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 416.23K | 769.77K | (1.06M) | 53.06K | 917.84K |
| Other Non-Cash Items | 144.76K | (227.4K) | 65.1K | (1.18K) | (276.84K) |
| Operating Cash Flow | (7.32M) | (13.59M) | (7.02M) | (1.85M) | (8.69M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | (7.16K) | (86.11K) | (89.73K) | (100.15K) |
| Common Stock Issued | 27.74M | 4.03M | 1.22M | 900.3K | 86.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.69M) | 1.17M | 1.06M | 0 | (360.14K) |
| Financing Cash Flow | 26.06M | 5.2M | 2.19M | 810.57K | 85.57M |
| Effect of Forex Changes | 223.79K | 258.82K | (45.35K) | 11.72K | 312.63K |
| Net Change in Cash | 18.96M | (8.13M) | (4.88M) | (1.03M) | 77.19M |
| Free Cash Flow | (7.32M) | (13.59M) | (7.02M) | (1.85M) | (8.69M) |
Bright Minds Biosciences Inc.
NASDAQ:DRUG
Intrinsic Alpha fair value
Locked
Current Price
$20.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.